Cantor Fitzgerald analyst Ross Osborn initiates coverage on $Anteris Technologies Global (AVR.US)$ with a buy rating, and sets the target price at $9.
According to TipRanks data, the analyst has a success rate of 40.0% and a total average return of -5.3% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Anteris Technologies Global (AVR.US)$'s main analysts recently are as follows:
The timing for Anteris Technologies' entry into the transcatheter aortic valve replacement market is considered opportune. The market is currently deeply entrenched between preferences for balloon-expandable valves and the requirements for hemodynamics in smaller valves. Anteris' DurAVR is believed to have the capability to deliver balloon-expandable valve technology across all valve sizes, which could cater to the increasing demands for valve replacement.
Anteris Technologies has created DurAVR, a unique, first-in-class biomimetic transcatheter aortic valve replacement platform, considered to have significant disruptive potential. The clinical development program has yielded impressive hemodynamic outcomes, distinguishing it within the sector and potentially enabling Anteris to secure a significant market share in the $10B TAVR market if these results are replicated in subsequent trials.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
坎托·菲茨杰拉德分析師Ross Osborn首次給予$安特瑞斯科技 (AVR.US)$買入評級，目標價9美元。
根據TipRanks數據顯示，該分析師近一年總勝率為40.0%，總平均回報率為-5.3%。
此外，綜合報道，$安特瑞斯科技 (AVR.US)$近期主要分析師觀點如下：
Anteris Technologies進入經導管主動脈瓣置換市場的時機被認爲是恰當的。目前，市場在對氣球膨脹閥門的偏好和對小型閥門血流動力學的要求之間根深蒂固。據信，Anteris的DuraVR能夠提供適用於所有閥門尺寸的氣球膨脹閥門技術，這可以滿足日益增長的閥門更換需求。
Anteris Technologies創建了DuraVR，這是一款獨一無二的、同類首創的仿生經導管主動脈瓣置換平台，被認爲具有巨大的顛覆潛力。該臨牀開發項目取得了令人印象深刻的血液動力學成果，使其在行業內脫穎而出，如果這些結果在後續試驗中得到複製，則有可能使Anteris在100億美元的TAVR市場中獲得重要的市場份額。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
